Oruka Therapeutics (NASDAQ:ORKA) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research report released on Thursday morning, Benzinga reports. HC Wainwright currently has a $45.00 target price on the stock.

ORKA has been the topic of several other research reports. Leerink Partners initiated coverage on shares of Oruka Therapeutics in a research note on Tuesday, September 17th. They set an “outperform” rating and a $44.00 price target on the stock. Stifel Nicolaus initiated coverage on shares of Oruka Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $49.00 target price on the stock. Jefferies Financial Group started coverage on Oruka Therapeutics in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 price target for the company. Wedbush began coverage on Oruka Therapeutics in a report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 price objective on the stock. Finally, Lifesci Capital started coverage on Oruka Therapeutics in a report on Monday, September 16th. They issued an “outperform” rating and a $41.00 target price for the company. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Oruka Therapeutics presently has an average rating of “Buy” and an average target price of $43.17.

Oruka Therapeutics Stock Performance

Shares of ORKA stock opened at $27.19 on Thursday. Oruka Therapeutics has a fifty-two week low of $18.72 and a fifty-two week high of $53.88. The business has a 50-day moving average price of $26.86. The firm has a market cap of $32.90 million, a price-to-earnings ratio of -4.53 and a beta of 0.87.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings data on Thursday, August 1st. The company reported ($25.92) EPS for the quarter. As a group, sell-side analysts forecast that Oruka Therapeutics will post -1.69 earnings per share for the current fiscal year.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.